By: Christine Mauceri, PharmD Candidate c/o 2025 On November 7th, 2024, the Food and Drug Administration (FDA) announced its proposal to remove oral phenylephrine from over-the-counter (OTC) drug products. Phenylephrine has been widely used, both orally and intranasally, for the temporary relief of nasal decongestion due to the common cold or allergies. It is marketed…

By: Nivaj Haque; PharmD Candidate c/o 2027 Recent advancements in cardiology have revolutionized the management of arrhythmias, offering new hope for patients with conditions like supraventricular tachycardia (SVT). Supraventricular tachycardia (SVT) significantly affects patients’ lives, leading to approximately 50,000 emergency department visits annually in the United States.1 This statistic underscores the urgency of developing effective…

By: Amita Singh, Pharm D Candidate c/o 2025 Voxelotor, marketed under the brand name Oxbryta, was approved by the US. Food and Drug administration (FDA) under the accelerated approval pathway in 2019 for the treatment of sickle cell anemia in adults and pediatric patients 12 years of age or older. In 2021, FDA granted accelerated…

By: Farzana Alam, PharmD Candidate c/o 2025, Anthony Autera, PharmD Candidate c/o 2025, Maha Saad, PharmD Background Drug pricing metrics are crucial in pharmacoeconomic analyses as they influence cost-effectiveness and budget impact studies. Selection of the most appropriate metric depends on the context of the analysis, the drug distribution channel, and payer perspective. The primary…